Important Dates and Deadlines
Full Paper Submissions
Conference & Registration
Increasing precision in translational metagenomics - the microbiome in medicine
Speaker: Ami Bhatt, PhD
Assistant Professor of Medicine (Hematology) and of Genetics
Dr. Jing-Shan “Jennifer” Hu is currently Partner of Qiming US healthcare Ventures. She brings extensive experience in partnering, licensing, R&D and management from three pharmaceutical multinational companies & two successful start-up and young biotech companies in the U.S. Prior to Qiming, she was VP of Bayer Healthcare and Head of its (External) Innovation Center China, responsible for partnerships for Global Drug Discovery with biotech and academia in Greater China. Before that, she was Director of Licensing & External Research at Merck & Co (MSD)’s for its worldwide licensing and partnering efforts on novel drug candidates and technologies from/with Greater China. She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics & VEGF-2 Project Leader. She has been successful in partnering with at least 25 biotech and top academic institutions in both the U.S. and China. Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD degree from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ. She was instrumental at leading a successful and peaceful transition of the community of SAPA-West to Chinese-American BioPharmaceutical Society (CABS) as the President of 2006-2007.
Giulia C. Kennedy is Chief Scientific Officer and Senior Vice President of Research, Product and Clinical Development for Veracyte. Since joining the genomic diagnostics company in 2008, Dr. Kennedy has overseen the development of three commercialized genomic tests that help reduce unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty. The company’s tests are setting new standards in disease diagnosis, where they are changing patient care and obtaining insurance coverage. Through Dr. Kennedy’s scientific leadership, Veracyte continually pushes the boundaries of what is possible in genomic diagnostics, using big data and machine learning to develop tests that answer critical clinical questions. Prior to Veracyte, Dr. Kennedy led the Genomics Collaborations and Genotyping Technology R&D groups at Affymetrix, Inc. Before that, she was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation, resulting in the identification of oncology markers for therapeutic drug development. Dr. Kennedy was previously a scientist at Millennium Pharmaceuticals, where she implemented genomic and genetic approaches to uncover diabetes susceptibility genes. She holds a Ph.D. degree in biochemistry, and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute. Dr. Kennedy has published more than 50 articles in peer-reviewed scientific journals and is a co-inventor on more than 20 patents.